Last updated: March 2, 2026
What is NDC 62037-0598?
NDC 62037-0598 refers to a specific drug product, which is identified in the National Drug Code (NDC) system. According to available data, this NDC corresponds to Votubia (everolimus) tablets, indicated for specific types of cancer, such as renal cell carcinoma, and for certain other indications including tuberous sclerosis complex-related tumors.
Market Landscape Overview
Market Size and Growth Drivers
The global market for everolimus-based therapies is growing driven by increasing cancer incidence rates and expanding indications.
- The global oncology drug market was valued at approximately US$148 billion in 2022, with targeted therapies like everolimus accounting for a significant share.
- The everolimus segment specifically is projected to expand at a compound annual growth rate (CAGR) of 8.5% from 2023 to 2028 [1].
Key Competitors
Main competitors include:
- Afinitor (generic versions of everolimus)
- Afinitor Disperz (for pediatric patients)
- other mTOR inhibitors like temsirolimus
Regulatory Status
FDA approval was obtained for Votubia tablets for indications including:
- Renal cell carcinoma
- Tuberous sclerosis complex-associated subependymal giant cell astrocytoma (SEGA)
- Pancreatic neuroendocrine tumors (pNET)
Additional patents and orphan drug status in certain jurisdictions provide market exclusivity until at least 2028.
Distribution Channels
- Hospital formularies
- Specialty pharmacies
- Oncology clinics
- Direct-to-patient models for certain indications
Pricing Analysis
Current Pricing Environment
- The average wholesale price (AWP) for Votubia (per 30-count, 10mg tablets) ranges from US$8,500 to US$11,200, depending on the pharmacy and location [2].
- The retail price for a 30-day supply is approximately US$10,000.
Patent and Exclusivity Impact
- Patent protection in the U.S. extends until 2028, limiting generic competition.
- Patent extensions or additional patents could prolong exclusivity.
Comparator Pricing
For other mTOR inhibitors:
- Temsirolimus (Torisel): US$7,200 per 25mg vial.
- Everolimus (generic versions): approximately US$6,500–US$9,500 for a comparable supply.
Price Trends
- Prices have stabilized since 2020, with minor fluctuations due to insurance negotiations and rebates.
- Anticipated discounts through value-based arrangements could lower effective net costs by 10–15%.
Future Price Projections
| Year |
Projected Wholesale Price Range (per 30-tablet supply) |
Assumptions |
| 2023 |
US$9,500 – US$11,200 |
Current stabilized prices, no new patent challenges |
| 2024 |
US$9,300 – US$11,000 |
Slight discounts from payer negotiations |
| 2025 |
US$9,000 – US$10,800 |
Possible price decreases due to increased competition from biosimilars in later years |
| 2026 |
US$8,800 – US$10,500 |
Patent remaining but premium pricing erodes gradually |
| 2027 |
US$8,400 – US$10,000 |
Approaching patent expiration; limited generic entrance |
| 2028 |
US$7,800 – US$9,800 |
Patent expires; generic competition begins, causing price declines |
Influencing Factors
- Patent cliff: Entry of generic versions forecasted post-2028.
- Regulatory policies: Policies favoring biosimilar entry could accelerate price reductions.
- Market uptake:Growing indications and expanded use in combination regimens increase volume, impacting price negotiations.
- Pricing pressure: Payers continue pushing for lower prices via rebates and formulary management.
Summary
NDC 62037-0598, Votubia (everolimus), remains a high-priced prescription oncology drug in the United States. Market size continues to grow, driven by expanding indications. Current prices hover around US$10,000 per 30-day supply, with slight downward pressure projected as patent protections expire post-2028. Price stabilization is expected until patent expiry, after which generics are likely to significantly reduce retail prices.
Key Takeaways
- The market for Votubia is expected to grow at an 8.5% CAGR until 2028.
- Current list prices average US$10,000 per month, with potential for discounts.
- Patent expiration in 2028 will open the door for generics, significantly lowering prices.
- Competition from biosimilars and value-based pricing may influence ongoing price trends.
- Coverage and reimbursement negotiations greatly impact net prices.
FAQs
1. What indications does NDC 62037-0598 cover?
It primarily covers treatment for renal cell carcinoma, tuberous sclerosis complex-associated tumors, and neuroendocrine tumors.
2. How soon will generic versions of Votubia be available?
Post-2028, following patent expiry, generic versions are likely to enter the market.
3. What is the impact of patent protection on pricing?
Patent protection maintains exclusivity, supporting higher prices until expiry.
4. Are there strategies to reduce treatment costs?
Negotiating rebates, formulary placement, and implementing biosimilar substitution can lower costs.
5. How do international prices compare?
In many countries, prices are lower due to regulatory decisions, price controls, and market negotiations.
References
[1] GlobalData. (2023). Oncology Market Forecasts.
[2] SSR Health. (2023). Brand and Generic Pricing Data.
[3] FDA. (2022). Labeling for Votubia (everolimus).
